Skip to content

All Episodes – Page 8

Browse our complete library of interviews and discussions with leading experts in oncology.

Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia

Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia

SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized cont

17 December 2024
13 min
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia

Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia

Audio Journal of Oncology Podcast December, 2024: Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia Hua Zhang MD PhD (Chief Scientific Officer with S

9 December 2024
7 min
Low Rates of Early Detection Drive Excess Breast Cancer Mortality in Underserved Communities

Low Rates of Early Detection Drive Excess Breast Cancer Mortality in Underserved Communities

BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United King

26 April 2023
25 min
AUDIO JOURNAL OF ONCOLOGY—Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma

AUDIO JOURNAL OF ONCOLOGY—Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma

Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best p

20 January 2023
16 min
AUDIO JOURNAL OF ONCOLOGY—Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma

AUDIO JOURNAL OF ONCOLOGY—Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical

9 January 2023
21 min
AUDIO JOURNAL OF ONCOLOGY—High Response Rates in Lung Cancer from Next Generation ROS1 Inhibitor 

AUDIO JOURNAL OF ONCOLOGY—High Response Rates in Lung Cancer from Next Generation ROS1 Inhibitor 

An interview with: Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, from the Yonsei Cancer Center at Yonsei University College of Medicine in Seoul, South Korea. BARCELONA, Spain—A “next gen

6 January 2023
12 min
AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy

AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy

ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine

5 January 2023
14 min
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study

Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i

4 January 2023
10 min
AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses

AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses

BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and

2 December 2022
9 min
Maria Reig MD PhD; ENA 2022 BARCELONA: AUDIO JOURNAL OF ONCOLOGY: ”New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma

Maria Reig MD PhD; ENA 2022 BARCELONA: AUDIO JOURNAL OF ONCOLOGY: ”New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma

New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma Interview with: Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona a

11 November 2022
18 min
AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma

AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma

PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immu

8 November 2022
6 min
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting

AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting

BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-

7 November 2022
9 min
AUDIO JOURNAL OF ONCOLOGY—First Line Atezolizumab Extends Life in Unfit Patients with Lung Cancer

AUDIO JOURNAL OF ONCOLOGY—First Line Atezolizumab Extends Life in Unfit Patients with Lung Cancer

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were

22 October 2022
7 min
AUDIO JOURNAL OF ONCOLOGY—Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer Therapy

AUDIO JOURNAL OF ONCOLOGY—Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer Therapy

HEIDELBERG, Germany—André Pfob, Clinical Research Assistant from the University Breast Unit at Heidelberg University Hospital, Germany tells the Audio Journal of Oncology’s correspondent Peter

14 October 2022
8 min
AUDIO JOURNAL OF ONCOLOGY—PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer

AUDIO JOURNAL OF ONCOLOGY—PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer

PARIS, France—Long remissions and potential cures were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancer

11 October 2022
6 min
Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis

ATLANTA, USA—A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into acute myeloid leukemia. Fin

10 October 2022
21 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 October 2019
10 min
Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism

Rivaroxaban Confirmed as Oral Alternative For Cancer Thromboembolism

ATLANTA—Six months follow up of the Select-D randomized open label multicenter pilot study with 406 patients has confirmed that therapy with the direct oral anticoagulant (DOAC) rivaroxaban was a safe

5 February 2018
15 min